JP3884693B2 - Formulations and functional foods that contain ultrafine powdered negative ion generating materials and far-infrared generating materials as active ingredients - Google Patents

Formulations and functional foods that contain ultrafine powdered negative ion generating materials and far-infrared generating materials as active ingredients Download PDF

Info

Publication number
JP3884693B2
JP3884693B2 JP2002299984A JP2002299984A JP3884693B2 JP 3884693 B2 JP3884693 B2 JP 3884693B2 JP 2002299984 A JP2002299984 A JP 2002299984A JP 2002299984 A JP2002299984 A JP 2002299984A JP 3884693 B2 JP3884693 B2 JP 3884693B2
Authority
JP
Japan
Prior art keywords
fat
sesame
particle size
average particle
bincho charcoal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002299984A
Other languages
Japanese (ja)
Other versions
JP2004131453A (en
Inventor
隆司 渡辺
行雄 柳本
Original Assignee
株式会社グラフィティ ツエンティワン
株式会社スキンクリエイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社グラフィティ ツエンティワン, 株式会社スキンクリエイト filed Critical 株式会社グラフィティ ツエンティワン
Priority to JP2002299984A priority Critical patent/JP3884693B2/en
Publication of JP2004131453A publication Critical patent/JP2004131453A/en
Application granted granted Critical
Publication of JP3884693B2 publication Critical patent/JP3884693B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Artificial Filaments (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化されたマイナスイオン発生素材のトルマリンあるいは遠赤外線発生素材の備長炭を有効成分として含む免疫機能の低下など生体の様々な障害の予防、改善などに有効な製剤及びかかる機能を有する機能性食品に関する。
【0002】
【従来の技術】
20世紀末期から始まった超高齢化社会と少子化社会の現象は、今世紀に入り益々その傾向が加速し、それと共に加齢変化に伴って生じ易くなると言われる生活習慣病もその定義が完全に崩れ、高齢層のみならず、若年層にまで浸襲し初めていることは周知のところである。このような状況から、21世紀に生きる人々の日常生活において、高齢層では、在宅介護者、長期入院慢性疾患患者、重度四肢・知的障害者に対する介護費・医療費が、今後日本経済をも揺るがす重大な問題となることが予測されている。
一方、学童・若年層の日常生活における不規則・不適切なバイオリズムや食生活、更には、不均衡な栄養食の摂取から、各種生活習慣病(高脂血症、高血圧症、糖尿病、骨粗鬆など)の増加は勿論のこと、自律神経失調症、免疫機能低下症、若年性痴呆症あるいは各種皮膚疾患(アトピー性/アレルギー性皮膚炎、潰瘍性皮膚疾患)などの発生・発症率の増加も近年顕著であり、これら年齢層が中高年齢期に達した場合を考えると、介護医療問題と同様、現在よりも更に重大かつ重要な社会問題に発展するであろうことは疑いのないところである。このような諸問題から、医療技術の向上や介護医療制度の抜本的改革と共に、まずは乳幼児期からの日常生活の見直しと改善・改革が早急に求められる所以である。
【0003】
ところで、アトピー性皮膚炎やアレルギー性皮膚炎を含む各臓器・器官に生じる各種アレルギー性疾患の発病・発症率は、近年、若年層を中心に年々上昇し、とりわけ乳幼児、学童児及び青年層においては、極めて顕著であり、日常の育児面や私生活面で多種多様の障害因子を生み出しているのが現状である。また、一般食品群中、従来より、小麦粉、鶏卵、そば粉、大豆などは強力なアレルゲンとしてアレルギー誘発材あるいは商品群であるが、最近では、これらに加えて日本人の主食である米、コラーゲン蛋白質及び茸類などがアレルゲンとして上位を占めるようになってきた。このことは、上述の年齢層間で、米飯、魚類、茸類を食する回数・機会が極度に少なくなってきたことに起因するものであり、ひいてはこのような食生活面の変化が、上述した皮膚疾患の発生・発症を急速に上昇させ、これに伴い抗アトピー剤や抗アレルギー剤の研究開発と製剤化が以前にも増して盛んに行われるようになってきている。各種皮膚疾患におけるアレルギー反応やアナフィラキシー反応に対しては、現在までのところ、化学物質製剤やステロイド系ホルモン製剤に依存しているが、これらの医薬品製剤によって完全な治療効果や再発抑制効果を期待できるものではないことは周知のところである。
【0004】
一方、上述したアトピー性/アレルギー性体質の乳幼児や学童児が、年々増加しているもう一つの主たる原因としては、食生活面の乱れのみならず、自然環境破壊や産業廃棄物の焼却に伴う弱酸性物質や成分が大気中に充満し、これらから発生するプラスイオンが考えられる。即ち、マイナスイオンとプラスイオンの生物にとっての理想的な比率が逆転し、その結果、生体外において異常閾値で常時暴露されると共に、生体内では、呼吸器系を介して体内に多量に取り込まれていることが上述した各種皮膚疾患誘発の要因となっていることも充分に想定される。
【0005】
このように、加齢変化と共に生体恒常性の維持力の低下、特に免疫機能や新陳代謝機能が低下し、高年齢層での日和見感染症を伴った各種皮膚疾患の治療対策は、若年齢層の食生活の乱れや環境汚染などによる外的因子によって生じ易くなっているであろうアトピー性/アレルギー性皮膚疾患と共に極めて難題であり、とりわけ養護・介護施設や在宅における完全介護を必要とする寝たきり老人層の感染症を主とした潰瘍性皮膚疾患や褥蒼の治療対策の確立も早急に求められる所以である。その一方で、多種に亘る皮膚疾患治療剤の中で近年注目されているのが、化学物質と天然植物由来組成物・成分を配合した製剤である。例えば、褥蒼や潰瘍性皮膚疾患に対して、有効性が認められている白糖・ポピドンヨード軟膏剤がある。しかし、ハロゲン族のヨウ素を主成分としているので、多量投与や長期投与による甲状腺機能への副作用あるいは長期保存下での効能の持続性の低下や薬剤の二層性分離による展延性の劣化などの短所が認められ、いまなお満足するに至る製剤とは言い難い(非特許文献1参照)。また、すべて、天然植物由来の組成物から成る製剤は、各種皮膚疾患や褥蒼の改善・治療に有効であることが多くの研究報告に見られ、かつ汎用されており、特に本発明者らによるコラーゲンペプチド・糖セラミド配合製剤(特許文献1参照)や電解竹酢液・シア脂配合製剤(特願2002−57972)は、上記各種皮膚疾患患者や褥蒼患者に対して、優れた改善治療効果を示す製剤である。しかしながら、その素材となる天然物由来の組成物を用いての製剤化には、多くの問題が残る。例えば、次の問題が考えられる。
1)有効成分画分のみを抽出・精製工程による高価な原料素材なる。2)天然由来であるので、商品化する際に原料素材の長期安定供給が困難である。3)天然植物由来の有効成分の含有量は、四季や樹齢に左右されるので、これらを無視しての無差別な採取や伐採が行われる可能性が生じる。4)精製されていないエキスや粉末を使用する場合、有効性の未知成分をも含有した製剤になる。
【0006】
一方、上述したように、自然環境破壊や産業破棄物の焼却によって、マイナスイオンとプラスイオンの比率が完全に逆転し、その結果、本来なら弱アルカリ性(pH7.35〜7.45)の生体内体液、血液、細胞外液が、プラスイオンの異常増加によって弱酸性化し、それに伴う各種疾患の発生・発症を防御する対策も今後の問題点であろう。即ち、多くの人々が生活している都会環境下で不足しているマイナスイオンを生体内に常時与えることにより、マイナスイオンとプラスイオンの比率を理想値(6:5)にまで戻す対策が生体恒常性の維持に今後極めて重要であろうと考えられる。
【0007】
天然の鉱物(鉱石)類は、原子間の電子(e)の出入りによって、大なり小なりマイナスイオン、即ち、電子を常時発生するため、従来より鉱物由来のマイナスイオン発生素材が製品化されている。このマイナスイオンの主たる作用効果としては、ホルミシス効果(細胞分裂促進、細胞機能活性化、血行促進作用など)による生体の生理学的機能(循環器系、神経系、免疫系、内分泌系)の低下予防、改善促進効果などがよく知られている。 また、遠赤外線発生素材の場合には、ジアテルミー効果(血管拡張、血流量増加、筋肉緊張緩和作用など)を発揮することが特色であり、同時にマイナスイオン発生機能をも有することは周知のことである。これらマイナスイオン発生素材や遠赤外線発生素材は極めて多種・多岐に亘る製品群が商品化されているが、これらの粒径はマイクロメートル(μm)オーダーの粒子(10〜50μm)である。
【0008】
【非特許文献1】
二神 孝次郎、他.最新医学:17;1369−1374、1992
【特許文献1】
特開2002−87989号公報
【0009】
【発明が解決しようとする課題】
しかしながら、従来のマイナスイオン発生素材や遠赤外線発生素材のような細菌・真菌サイズと同一レベルのマイクロメートル(μm)オーダーの粒子あるいは粉末から発生するマイナスイオン量(mmシーベルト/cm)と、ウイルスサイズと同一レベルのナノメートル(nm=10−9m)オーダーの粒子から発生するマイナスイオン量を比較した場合、水分子(自然界における水蒸気中の水分子(ミスト)は0.5〜100nmである)にみられるレナード効果と同様にマイナスイオン発生素材の粒径を細かくすればする程、電子の発生量・発生率(マイナスイオンの発生量)は、増量・増幅され、しかも幅広く、常時均一に発生させることが十分に可能であると考えられる。現に大気中のマイナスイオンの粒径は1〜20nmであると言われているので、マイナスイオン発生素材や遠赤外線発生素材をナノメートルのオーダーにまで超微粉末化することにより、その応用・用途、特に医療を目的とした応用・用途範囲は更に拡大される可能性は極めて大であり期待されるところである。
【0010】
そこで、本発明は上記事情に鑑みなされたものであり、マイナスイオンのホルミシス効果や遠赤外線のジアテルミー効果を十分に発揮し得るマイナスイオン発生素材のトルマリ あるいは遠赤外線発生素材の備長炭を主要成分とする製剤及び機能性食品を提供することを課題とする。
【0011】
【課題を解決するための手段】
本発明者らは、上記課題を解決するためにマイナスイオン発生素材のトルマリンあるいは遠赤外線発生素材の備長炭をナノメートルオーダーにまで超微粉末化し、これらを既に研究報告されている抗炎症作用を有するセサム脂などやコラーゲン・エラスチン分解酵素の阻害成分と増殖因子受容体構成成分である糖セラミドなどを混合した配合剤とを組み合わせ、実験的に皮膚炎創傷部位が惹起された動物あるいは実験的に免疫不全が惹起された動物を用い、その薬理活性について鋭意検討を重ねることにより本発明を完成した。
すなわち、本発明は、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化されたトルマリン及び/又は備長炭を有効成分として含む免疫機能低下予防及び/又は改善剤に関する。この発明は、マイナスイオン発生素材のトルマリンや遠赤外線発生素材の備長炭を平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化することにより、マイナスイオンのホルミシス効果や遠赤外線のジアテルミー効果を高めたものである。
【0012】
本発明は、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、を有効成分として含む炎症性創傷皮膚組織再生機能改善促進剤、新陳代謝機能改善亢進剤、アトピー性又はアレルギー性皮膚炎改善促進剤、潰瘍性皮膚疾患改善促進剤あるいは発毛・育毛促進剤に関する。また、本発明は、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化されたトルマリン及び/又は備長炭と、セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、を有効成分として含む免疫機能低下予防及び/又は改善剤に関する。該発明は、超微粉末化されジアテルミー効果が高められた備長炭とセサム脂や糖セラミドなどを組み合わせることにより、相乗的に薬理活性を増幅するものである。なお、炎症性創傷皮膚組織再生機能改善促進剤とは、生体内の諸種成分の同化・異化作用などによって、主として生体組織構成成分の再生や形成機能を促進させる製剤をいい、新陳代謝機能改善亢進剤とは、皮膚・皮下組織構成成分や関連細胞群の加齢変化や環境汚染(有害物質、原子、原子団イオンなど)による不測の生体変調によって生じ易くなる新陳代謝機能や免疫機能の低下を緩解し、且つ改善促進させる製剤をいう。
【0013】
また、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭を含む機能性食品に関する。また、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、を含む機能性食品に関する。
【0014】
【発明の実施の形態】
本発明のマイナスイオン発生素材はトルマリンを用い、遠赤外線発生素材は備長炭を用いる。
【0015】
現在、利用・応用されている鉱物や植物由来素材粉末の粒径は、最小でも10〜30μmレベルであるが、トルマリンあるいは備長炭は、ナノメートルオーダーに超微粉末化される。超微粉末化は、例えば、特公平7−4553号公報に記載の粉砕技術製造法により行うことができ、この製造法によれば平均粒径と粒度分布が制御された超微粉末を得ることができ、より具体的には株式会社アロマ化学機械工業社製の粉砕装置を用いて行うことができる。ナノメートルオーダーとは、1μmよりさらに1/1000小さい単位をいう。
【0016】
セサム脂又はセサム脂主要成分画分は、市販品を容易に入手することができ、例えば、九鬼産業株式会社製のセサム脂を用いることができる。尚、セサム脂主要成分画分とは、セサミン誘導体やフィトステロイド誘導体などセサム脂に主として含有される成分をいい、これらを糖セラミドなどと共に用いることもできる。シア脂(シアバターともいう)は、セサム脂と共通主要成分(フィトステロイド類、必須不飽和脂肪酸類、テルペノイド類)を豊富に含有しており(特願2002−57972)、例えば中央アフリカ原産のシア果実由来のシア脂を用いることができ、このようなシア脂はアイ・エム・シー株式会社から容易に入手することができる。
【0017】
糖セラミドは、小麦胚芽、米糠、麹などに含まれ、動物細胞にも含まれる糖脂質の一種である。セラミド本体は、化学的合成法によっても製造可能であるが、糖(特に、グルコース)をスフィンゴシン骨格に結合させることは極めて困難かつ高価となる。従って、本発明の糖セラミドは、天然物由来のものを好適に用いることができ、市販品を容易に入手することができる。尤も、強度のアレルギー誘発食材である小麦由来のものは留意する必要がある。
【0018】
超微粉末化されたトルマリンあるいは備長炭(以下、それぞれ「超微粉末化トルマリン」又は「超微粉末化備長炭」ということがある)は、単独でも免疫機能低下予防及び/改善剤の有効成分として用いることができるが、セサム脂、セサム脂主要成分画分、シア脂あるいは糖セラミドと組み合わて用いることにより、炎症性創傷皮膚組織再生機能改善促進剤、新陳代謝機能改善亢進剤、アトピー性又はアレルギー性皮膚炎改善促進剤、潰瘍性皮膚疾患改善促進剤、免疫機能低下予防及び/又は改善剤あるいは発毛・育毛促進剤の有効成分として用いることができる。これら薬剤の投与形態は、塗布・塗末が一般的であるが、これらに限定されるものではない。
【0019】
本発明の製剤は、剤型も用途に応じて適宜選択でき、薬剤的に許容される賦形剤、崩壊剤、軟膏基剤、乳化基剤、乳状基剤、クリーム基剤、薬用洗浄用基剤を用いて、軟膏剤、塗布剤、湿布剤、薬用乳状製剤、各種薬用又は発毛・育毛用ジェル・ローション剤などの剤型に供することができると共に、散剤、顆粒剤、錠剤、カプセル剤、座剤などの医療用製剤として供することもできる。
【0020】
また、本発明の製剤は、それらの薬効を失わない限り、他の薬効や諸種生体機能亢進作用を有する成分あるいは製剤(動植物由来のものを含む)を配合して医療用製剤として供することもできる。例えば、加齢変化と共に漸減する自己コラーゲンや軟骨成分を生体内で再合成させるために必要な基本・必須成分であるグルコサミン、コンドロイチン、ヒアルロン酸及びビタミンC(理想的比率:グルコサミン:コンドロイチン:ヒアルロン酸:ビタミンC=10:10:2:1)を添加配合することにより、自己コラーゲンの再合成が可能となるため、現在用いられている各種動物・魚類由来コラーゲンの塗布や服用が不必要になる。しかも、皮膚のシミやシワ形成の予防・緩解・軽減を促進する軟膏剤や化粧品(クリーム、ジェル、エッセンス、ローション液、化粧用石鹸など)として供することもできる。更には、強力な抗アレルギー作用と免疫賦活作用を有することが知られる甲殻類(カニ、エビなど)由来キトサン(粉末、水溶性)などを添加することにより、本発明の上記の製剤類の作用効果を相乗的かつ有効に高めることも可能である。
【0021】
また、特に新陳代謝機能改善亢進作用及び免疫機能低下予防改善作用を期待して、本発明の超微粉末化トルマリン超微粉末化備長炭、あるいはこれらにセサム脂、セサム脂主要成分画分、シア脂、糖セラミドを組み合わせて含有させる機能性食品を供することができる。この機能性食品によれば、加齢変化に顕著な生体恒常性の低下を予防・改善でき、介護食や栄養補助食に配合しても良い。また、ゼリー、ヨーグルトなどの固形食品にも添加が可能である。
【0022】
本発明の製剤における、超微粉末化トルマリン超微粉末化備長炭、あるいはセサム脂、セサム脂主要成分画分、シア脂、糖セラミドの配合割合は、各種製剤100重量部に対して、超微粉末化トルマリンは0.2〜0.6重量部、超微粉末化備長炭は0.1〜0.5重量部、セサム脂、セサム脂主要成分画分あるいはシア脂は0.5〜5.0重量部、糖セラミドは0.1〜0.3重量部が好ましい。これらの下限を下回れば、添加物間の十分な相乗的作用効果が得られないことがあり、また、上限を上回れば、免疫担当細胞群、特に免疫機能作動時の第一細胞であるマクロファージに対する抗原性が過飽和状態になり、マクロファージの機能性を阻止する可能性があるからである。これらのことを勘案した上、本発明の各種製剤が十分な効果を発揮し得るためには、各種製剤の摂取量は50kg体重当たり5〜10g/日が好ましく、これを1日2〜3回に分けて使用しても良い。勿論、使用される対象者の年齢、症状、体調などを考慮し、摂取量を適宜増減させることができる。
【0023】
【実施例】
次いで、本発明を実施例を挙げて説明するが、本発明は以下の実施例に限定されるものではない。
【0024】
〔実施例1〕実験的炎症性皮膚炎創傷部位の作製法及び炎症部位の面積測定法
7週齢のddY系正常雌マウス(平均体重:32g、SLC社製)の腹腔内にチオペンタールナトリウム麻酔剤(ラボナール、万有製薬社製)の0.1ml(24mg/ml、75mg/kg)を投与した。麻酔下の動物に対して、電気バリカンと除毛クリーム剤にて、背部の毛を完全除毛した後、特製電気ドライヤー(口径:3cm、800V/100W)をマウス背部面と直角になるように設置し、10cmの高さから除毛部背部面を60秒間照射(80℃)し、アトピー性/アレルギー性皮膚炎症部位(平均8cm)を作製した(図1参照)。なお、この実験方法では、1度の熱傷(角質部から表皮層に至る創傷)に相当した。また、この方法で作製した動物血液中の白血球分類(染色法)と免疫グロブリンE(IgE)抗体価(EIA法)を測定したところ、正常対照群に比べて、好塩基球及び抗体価が著しく上昇していたことから、アトピー性皮膚炎/アレルギー性皮膚炎が実験的に惹起されていることが確認された。皮膚炎症部位作製直後から28日間に亘り、麻酔下のマウス背部炎症皮膚表面にセロファン紙を当てて、炎症部位面及び再発毛部位面をマーカーでトレースし、画像解析装置(Modulator System MOP−AM03、コントロン社製、ドイツ)にて、各々の面積を計測した。マウス背部炎症皮膚表面の創傷面積は、次の計算式で求めた。
創傷面積(mm)=炎症皮膚面総面積−再発毛面総面積
【0025】
〔実施例2〕実験用配合クリームの作製法
各種成分非含有クリーム基剤に、後記の各種薬剤100重量部に対して超微粉末化トルマリンは0.5重量部、超微粉末化備長炭は0.5重量部、セサム脂は3.8重量部、糖セラミドは0.2重量部の割合で混合し、作製した。また、トルマリンと備長炭は、株式会社アロマ化学機械工業社製の粉砕装置を用いて各々平均粒径10nmと30nmに超微粉末化した。
【0026】
〔実施例3〕実験的炎症性皮膚創傷面の縮小と治癒推移
本実験系は、(1)クリーム基剤単独塗布対照群(2)セサム脂・糖セラミド(以下、SCともいう)配合剤塗布群(3)超微粉末化備長炭(以下、ナノ・Cともいう)含有SC(以下、ナノ・C−SCともいう)配合剤塗布群(4)ナノ・C−SCに超微粉末化トルマリン(以下、ナノ・Tともいう)を添加したナノ・TC−SC配合剤塗布群の計4群(各群:5匹宛)を準備し、以下の実験を行った。すなわち、マウス背部皮膚面に、実施例1に記載した方法で実験的皮膚炎を起こさせた直後(0日目)、1、3及び5日目に実施例2で作製した上記の各配合剤(0.5g/スパーテル/マウス)をガラスコンラッジ棒で塗布・展延(計4回)した後、28日間に亘って炎症部位の面積を実施例1の方法で計測した。その結果を表1に示す(図2、3参照)。この表に示すように、炎症性皮膚創傷面直後の創傷面積は、6.30±0.45cmであった。このような実験的炎症惹起マウスを用いて、実験を行ったところ、クリーム基剤塗布対照群における7、14及び21日目の炎症性皮膚創傷面積は、5.88±0.31、3.28±0.38、2.02±0.45cmであり、日数の経過と共に徐々に炎症部位の治癒傾向がみられた。これに対して、SC配合剤塗布群では、14日目に有意差(危険率:5%以下、検定法:Student t−test法)が認められた。一方、ナノ・C−SC配合剤塗布群の治癒促進効果は、SC配合剤塗布群よりも顕著であり、7日目に既に有意性(危険率:5%以下)が観察された。また、ナノ・TC−SC配合剤塗布群の治癒効果は、ナノ・C−SC配合剤塗布群よりも更に強力で、7日目には危険率1%以下の有意差を示し、7日目、14日目及び21日目の創傷面積は、3.71±0.58、0.63±0.14及び0.01±0.02cmであった。一方、ナノ・シリーズ配合剤の塗布によって、発毛部位面積が、日数の経過と共に著しく展延したことから、これら配合剤には、発毛・育毛促進作用、すなわち毛包細胞(毛母根、毛乳頭)増殖促進作用をも有するであろうことも明らかになった。
【0027】
【表1】

Figure 0003884693
【0028】
〔実施例4〕実験的炎症性皮膚創傷面の完全治癒マウス百分率の推移
実施例3に記載した4群の実験系に超微粉末化トルマリン(T)をSC配合剤に添加したナノ・T−SC配合剤塗布群を加えた計5群(各群:10匹宛)の21日目及び28日目における炎症性皮膚創傷面の完全治癒百分率の推移を調べた。その結果を表2に示す(図4参照)。この表に示すように、クリーム基剤塗布対照群における完全治癒率は、21日目で10%、28日目で20%に過ぎなかったが、SC配合剤塗布群では、多少とも上昇し、28日目の完全治癒率は40%であった。一方、このSC配合剤に超微粉末化備長炭(C)あるいは超微粉末化トルマリン(T)を添加することによって、完全治癒率は更に上昇し、21日目には50〜60%に達した。これに対して、ナノ・TC−SC配合剤塗布群では、21日目で既に80%の完全治癒率が観察された。これらの結果から、超微粉末化マイナスイオン発生素材及び遠赤外線発生素材を混合・配合することにより、炎症性皮膚創傷面の治癒は相乗的に促進されることが確認された。即ち、マイナスイオンのホルミシス効果と遠赤外線のジアテルミー効果の相乗的効果作用に起因するものであろうことが示唆された。
【0029】
【表2】
Figure 0003884693
【0030】
〔実施例5〕実験的炎症性皮膚組織内浸潤細胞数と細胞分類
実施例4に記載した実験系5群への各種配合剤塗布7日目における創傷皮膚表皮層から真皮層内に10%胎児牛血清加イーグルMEM(ヘパリン:4単位/ml)培養液(以下、培養液)5mlを注入し、背部皮膚を十分に揉みほぐした後、注入培養液を5ml用注射器で回収し、その1.0mlをプラスチックマイクロプレート(直径:30mm、6ウエル)に移した。マイクロプレートを37℃下、2時間保温後、培養液を静かに除去し、ウエルのリン酸緩衝液洗浄、メタノール固定、ギムザ染色を行い、ウエル上の浸潤細胞数及び浸潤細胞分類を顕微鏡下で算出した。その結果、表3の左側に示すように、SC配合剤塗布群の総浸潤細胞数(平均:2.2×10コ/ウエル)は、クリーム基剤塗布対照群のそれよりも約2倍の値まで上昇したが、両群間に有意差は認められなかった。一方、このSC配合剤に、超微粉末化備長炭や超微粉末化トルマリンを添加することにより、総浸潤細胞数は著しく上昇し、クリーム基剤塗布対照群の約7倍を示した。また、これら2種の超微粉末を混合・配合したナノ・TC−SC配合剤塗布群における総浸潤細胞数は、実に10倍(平均2.6×10コ/ウエル)に達し、危険率も0.01%以下であった。
他方、これら浸潤細胞を分類したところ、表3の右側に示すように、クリーム基剤塗布対照群では、リンパ球様細胞が最も多く、平均89.5%であり、マクロファージ様細胞及び上皮性/繊維芽性細胞は、8.2%及び2.3%に過ぎなかった。この傾向は、SC配合剤塗布においても同様の結果であった。しかし、このSC配合剤に超微粉末化備長炭や超微粉末化トルマリンを添加することにより、あるいはこれら2種の超微粉末を添加することによりマクロファージ様細胞(MP、平均46〜52%)と上皮性/繊維芽性細胞(平均6〜20%)が著しく上昇していることが認められ、特にナノ・TC−SC配合剤塗布群で顕著であった(MP:平均52.2%、上皮性/繊維芽性細胞:平均20.4%)。
これらの結果から、超微粉末化備長炭や超微粉末化トルマリンを添加することによって、免疫機能が賦活されることや、更には、皮膚・皮下組織関連細胞群の分裂・増殖をも促進されるであろうことが推定された。
【0031】
【表3】
Figure 0003884693
【0032】
〔実施例6〕実験的炎症性皮膚創傷面の皮膚・皮下組織の病理組織学的検査
次に、上記の実施例5で述べた推論(SC配合剤に超微粉末化備長炭や超微粉末化トルマリンの添加による皮膚組織関連上皮細胞や繊維芽細胞の増加は、マイナスイオンのホルミシス効果に起因しており、更には、コラーゲンやエラスチンなどの膠原蛋白質類の再合成も促進されるであろう)を立証するために、以下の検討を行った。実施例4に記載の5群中、クリーム基剤塗布対照群、ナノ・T−SC配合剤塗布群及びナノ・C−SC配合剤塗布群の3群の14日目における平均炎症部位面積に最も近いマウスの背部創傷面皮膚組織を切除し、常法に準じて処理した。即ち、脱水処理(アルコール濃度勾配)、固定(1%グルタルアルデヒド、1%パラホルムアルデヒド混液)、パラフィン包埋した後、皮膚組織切片を作製した。結合組織(膠原)蛋白質を特異的に染め分けるエラスチカ、ファン ギーソン染色法で染色し、特に皮下組織内の結合組織(膠原繊維、弾力繊維、コラーゲン、エラスチンなど)の再生、形成の進展程度を顕微鏡下で観察した。その結果を図5に示す。炎症部位作製直後の皮膚組織切片像(図5右端)では、上記染色液で赤〜桃紅色に染められるはずの部分は全く認められず、皮膚層及び組織そのものが完全に壊死状態にあることが確認された。これに対して、クリーム基剤塗布対照群の皮膚組織切片像では、桃色に染色された部分は点在し、そして上皮性(円形)細胞や繊維芽性細胞(紡錘形)群の浸潤は角質層下部の基底膜から真皮層、皮下組織に達し、基底膜の形成過程を含めて、皮膚組織全体の再生機転は、今尚初期段階であることが確認された。これに対して、超微粉末化備長炭や超微粉末化トルマリンを添加することによりナノ・C−SC配合剤塗布群及びナノ・T−SC配合剤塗布群の組織切片像においては、上述した細胞群は真皮層から皮下組織層にかけ殆ど認められなかったが、組織の全面が鮮やかな桃紅色に染色されていた。
即ち、膠原蛋白質類(コラーゲン、エラスチン)の形成がほぼ完了し、角質層、基底膜、表皮層及び真皮層の再形成はもはや終了している所見であった。このことは、表3に示した7日目におけるナノ・C−SC配合剤塗布群及びナノ・T−SC配合剤塗布群では、上皮性/繊維芽性細胞群の増加現象が著しかったことから、14日目には、これら細胞群により膠原蛋白質類の再合成が完了し、その結果、これら細胞群のフィードバックと共に、組織切片全体が濃い桃紅色に染色されたものであろうことが確認された。
【0033】
〔実施例7〕デキサメサゾン処理免疫機能不全動物の作製法
副腎皮質ホルモン系デキサメサゾン(デカドロン、田辺製薬社製)を用いて、本発明者らにより変法(J.Jpn.Associ.Dis.70:574−582,1996)に従って行った。即ち、デキサメサゾン(DM)液(1.0mg/ml)の0.3ml(11.5mg/kg/日)を5週齢雌マウス(平均体重26g)の腹腔内に、0、1、3及び5日目の計4回に亘って接種することにより、免疫機能低下・減弱マウスを作製した(以下、DM処理マウスという)。
【0034】
〔実施例8〕超微粉末化トリマリンと超微粉末化備長炭のDM処理マウス腹腔内滲出細胞数及び細胞百分率に及ぼす効果
実施例7で作製されたDM処理マウス(各群:3匹宛)に対して、最終DM処理(4回目接種)後、1日目に超微粉化トルマリンと超微粉化備長炭の溶解液0.2ml(0.1mg/ml生理食塩水:7.7mg/kg)を各々マウス腹腔内に投与した。尚、対照群として非投与正常群とDM処理単独群(各群:3匹宛)を各々準備した。上記の2種の超微粉末の溶解液を投与後、3日目に実施例5で行ったのと同様の方法で、腹腔内滲出細胞を培養し、実施例5と同様の方法で洗浄、固定、染色後、マイクロプレートのウエル上の総細胞数と各種細胞の分類を顕微鏡下で算定した。その結果を表4に示した(図6参照)。
この表の左側に示すように、腹腔内滲出総細胞数において、非投与正常対照群(平均2.2×10コ/ウエル)とDM処理単独群(2.6×10コ/ウエル)間における有意差は著しく(危険率:0.05%以下)、DMでの4回処理によって、免疫担当細胞群が著しく低下したことから、DMの免疫機能への障害作用は顕著であることが推定された。このような免疫機能減弱・不全マウスに超微粉末化トルマリンあるいは超微粉末化備長炭をDM処理マウス腹腔内に投与したところ、いずれの投与群においても総細胞数の顕著な増加がみられ、その数は非投与正常対照群のそれと近似もしくはそれ以上の値(平均:3.0〜4.5×10コ/ウエル)にまで達した(危険率:0.01%以下)。一方、この表の右側に示すように、DM処理によって減少する細胞群はマクロファージであり、供試した超微粉化トルマリンと超微粉化備長炭には、減少したマクロファージ数を再び増加させる作用を有すること、即ち、これら超微粉末は、免疫機能回復作用、特にマクロファージ機能亢進効果を示すことが明らかにされた。
【0035】
【表4】
Figure 0003884693
【0036】
〔実施例9〕超微粉化トルマリンと超微粉化備長炭のDM処理マウス腹腔内マクロファージに対する貪食機能回復増強効果
実施例8でで述べた推論(表4参照)、即ち、超微粉末化されたトルマリンあるいは備長炭のマクロファージ機能改善・促進作用の有無について以下の実験を行った。即ち、実施例8に記載した3群について、同様の方法で採取した腹腔内滲出液1mlをマイクロプレートに移し、37℃下で3時間培養、洗浄後、加熱処理したメチシリン耐性黄色ブドウ球(MRSA)菌を培養細胞1コ当たり、20生菌単位(CFU)のMRSA菌(MOI=20)になるように調製した菌液1mlを添加し、更に、37℃下、2時間保温し貪食実験を行った。その後、実施例5に記載した方法に準じて作製された標本について、MRSA菌に対するマクロファージ(MP)の貪食率及びMP1コ当たりに貪食されたMRSA菌数を算定した。その結果を表5に示した(図7参照)。この表の左側に示すように、非投与正常対照群由来マクロファージ(MP)のMRSA菌に対する貪食率は、平均46.5%であったが、DM処理によって、その貪食率は著しく低下した(平均4.9%)。このようなDM処理マウスに、超微粉末化トルマリンあるいは超微粉末化備長炭を腹腔内投与することによって、MP貪食率は平均56.6%及び67.2%にまで上昇し、しかも正常対照群MPを上回る値であった。一方、表5の右側に示すように、正常対照群由来マクロファージ(MP)1コ当たりに貪食されたMRSA菌の菌数は平均4.8コであったが、DM処理群のMPでは平均0.6コであり、MPの貪食機能は著しく障害されていた。しかし、供試した2種の超微粉末を腹腔内投与したところ、減弱していたマクロファージの貪食機能は著しく回復し、しかも増強されており(平均9.4〜12.1%)、DM処理群由来のMPの貪食機能の実に11〜13倍にまで達していた。
【0037】
【表5】
Figure 0003884693
【0038】
〔実施例10〕安全性試験の検討
1)50%致死量
ddY系雌及び雄マウス(5週齢)の1群5匹準備し、超微粉末化トルマリンと超微粉末化備長炭の経口投与と腹腔内投与によるマウスの死亡数を7日間に亘って記録し、これら製剤の50%致死量をベーレンス・カーバー法に従って求めた。その結果、両製剤の経口投与による50%致死量は、雌雄を問わず、1700mg/kg以上、腹腔内投与で50%致死量は、5900mg/kgであった。
2)光感作性(アレルギー性)、皮膚一次刺激試験
ナノ・TC−SC配合剤添加クリーム又はローションの健康者(30名)に対する光感作性(アレルギー性)、皮膚一次刺激試験を行ったところ、いずれの試験においても陰性であった。
【0039】
〔実施例11〕炎症性創傷皮膚組織再生機能改善剤
クリーム基剤10gに、表6に記載の各成分を混合し、クリーム基剤で100gになるように調整し、目的とする製剤を製した。尚、この処方は、皮膚内でのコラーゲンをも新生させる目的をも含む製剤である。
【0040】
【表6】
Figure 0003884693
【0041】
〔実施例12〕抗アトピー性/アレルギー性皮膚炎症用軟膏剤
クリーム基剤10gに、表7に記載の各成分を添加・混合し、更に白色ワセリンにて全量100gとし、目的とする製剤を製した。
【0042】
【表7】
Figure 0003884693
【0043】
〔実施例13〕機能性食品
表8に記載の各成分をヨーグルト原料、ゼリー原料あるいはプリン原料に添加して全量100gとし、新陳代謝機能亢進及び免疫機能低下予防・改善用の機能性食品を製した。
【0044】
【表8】
Figure 0003884693
【0045】
【発明の効果】
本発明は、上記のように構成されるため、以下の効果を奏する。
本発明によれば、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化されたトルマリン及び/又は備長炭を有効成分とするので、マイナスイオンのホルミシス効果や遠赤外線のジアテルミー効果が高められ、免疫機能低下を予防及び/又は改善する作用に優れる。
【0046】
本発明によれば、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、を有効成分とし、あるいは平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化されたトルマリン及び/又は備長炭と、セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、を有効成分とするので、ホルミシス効果やジアテルミー効果が高められたトルマリン備長炭とセサム脂や糖セラミドなどとの組み合わせにより、相乗的に薬理活性が増幅されるので、様々な優れた薬理活性を奏し、特に炎症性創傷皮膚組織再生機能改善促進作用、新陳代謝機能改善亢進作用、アトピー性又はアレルギー性皮膚炎改善促進作用、潰瘍性皮膚疾患改善促進作用、免疫機能低下予防及び/又は改善作用あるいは発毛・育毛促進作用に優れた製剤を提供できる。
【0047】
本発明によれば、平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭、あるいは平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と組み合わせたものを機能性食品として食品に添加することができるので、特に新陳代謝機能改善亢進作用及び免疫機能低下予防改善作用を有する食事を日常の食生活において摂取できる。
【図面の簡単な説明】
【図1】実験的なマウス背部への炎症性皮膚創傷面の作製方法とアトピー性/アレルギー性皮膚創傷面作製直後のマウスの背部創傷面像
【図2】各種配合剤の塗布後7日目のマウスの背部創傷面像
【図3】各種配合剤の塗布後14日目のマウスの背部創傷面像
【図4】各種配合剤の塗布後21日目のマウスの背部創傷面像
【図5】各種配合剤の塗布後14日目のマウスの背部創傷皮下組織の顕微鏡写真像
【図6】DM処理免疫不全マウス腹腔内滲出免疫担当細胞群の顕微鏡写真像
【図7】DM処理免疫不全マウス腹腔マクロファージのMRSA菌貪食像[0001]
BACKGROUND OF THE INVENTION
  The present invention has an average particle size of nanometers (10-9m) Ultra-fine powdered negative ion generating materialTourmalineOr far infrared ray generation materialNo bincho charcoalThe present invention relates to a preparation effective for the prevention and improvement of various disorders of the living body, such as a decrease in immune function, and functional foods having such a function.
[0002]
[Prior art]
  The phenomenon of the super-aging society and the declining birthrate that began at the end of the 20th century has accelerated its tendency toward the beginning of this century, and the definition of lifestyle-related diseases, which are said to be more likely to occur with aging, is completely defined. It is well known that it has collapsed and has begun to invade not only the elderly but also the younger generation. Under these circumstances, in the daily life of people living in the 21st century, in the elderly, care and medical expenses for home caregivers, long-term hospitalized patients with chronic illness, severe limbs and people with intellectual disabilities will continue to grow in the Japanese economy. It is expected to be a serious problem that shakes.
  On the other hand, irregular and inappropriate biorhythms and dietary habits in daily life of school children and young people, as well as ingestion of unbalanced nutrients, have led to various lifestyle-related diseases (hyperlipidemia, hypertension, diabetes, osteoporosis). Increasing incidence and incidence of autonomic ataxia, hypoimmuneism, juvenile dementia or various skin diseases (atopic / allergic dermatitis, ulcerative skin disease) In recent years, when these age groups have reached middle-aged age, there is no doubt that they will develop into more serious and important social problems than today, as well as nursing care problems. . Because of these problems, first of all, the improvement of medical technology and the fundamental reform of the nursing care system, as well as the urgent need for a review and improvement / reform of daily life from the early childhood.
[0003]
  Meanwhile, the incidence and incidence of various allergic diseases that occur in various organs and organs, including atopic dermatitis and allergic dermatitis, have been increasing year by year mainly in young people, especially in infants, school children and adolescents. Is extremely prominent and currently produces a wide variety of disability factors in terms of daily childcare and private life. Also, among the general food groups, wheat flour, chicken eggs, buckwheat flour, soybeans, etc. are allergens or product groups as powerful allergens, but recently, in addition to these, rice, collagen, which are Japanese staple foods. Proteins and moss have come to occupy the top ranks as allergens. This is due to the fact that the number and opportunity of eating rice, fish, and potatoes has become extremely small among the above-mentioned age groups, and as a result, such changes in dietary habits have been described above. With the rapid increase in the occurrence and onset of skin diseases, research and development and formulation of anti-atopic agents and anti-allergic agents are becoming increasingly popular. Until now, allergic reactions and anaphylactic reactions in various skin diseases depend on chemical preparations and steroidal hormone preparations, but these pharmaceutical preparations can be expected to have complete therapeutic effects and relapse suppression effects. It is well known that it is not a thing.
[0004]
  On the other hand, the main cause of the increase in the number of infants and schoolchildren with atopic / allergic properties mentioned above is not only due to disturbances in the eating habits, but also due to destruction of the natural environment and incineration of industrial waste. Weakly acidic substances and components fill the atmosphere, and positive ions generated from these are considered. In other words, the ideal ratio of negative ions to positive ions for living organisms is reversed, and as a result, they are constantly exposed to abnormal threshold values outside the living body, and in vivo, a large amount is taken into the body via the respiratory system. It is fully assumed that this is a factor in inducing various skin diseases described above.
[0005]
  In this way, the ability to maintain homeostasis with age-related changes, especially the decline in immune function and metabolic function, treatment measures for various skin diseases associated with opportunistic infections in older age groups, Bedridden elderly people who are extremely difficult with atopic / allergic skin diseases that are likely to be caused by external factors due to disturbance of eating habits and environmental pollution, especially those who need complete care in nursing homes or nursing homes or at home The establishment of treatment measures for ulcerative skin diseases and hemorrhoids, mainly infectious diseases, is also urgently required. On the other hand, among various therapeutic agents for skin diseases, a preparation that is recently attracting attention is a preparation containing a chemical substance and a natural plant-derived composition / component. For example, there is a sucrose / popidone iodine ointment that has been shown to be effective against wrinkles and ulcerative skin diseases. However, because it contains halogen group iodine as the main component, side effects on thyroid function due to large doses or long-term administration, decrease in sustainability of efficacy under long-term storage, and deterioration of spreadability due to bilayer separation of drugs, etc. Disadvantages are recognized and it is difficult to say that the preparation is still satisfactory (see Non-Patent Document 1). In addition, all the preparations composed of compositions derived from natural plants have been found in many research reports to be effective in the improvement and treatment of various skin diseases and wrinkles, and have been widely used. Collagen peptide / sugar ceramide combination preparation (see Patent Document 1) and electrolytic bamboo vinegar / shea fat combination preparation (Japanese Patent Application No. 2002-57972) are excellent improvement treatments for the above-mentioned various skin disease patients and epilepsy patients. It is a preparation showing an effect. However, many problems remain in formulation using a composition derived from a natural product as a raw material. For example, the following problem can be considered.
1) It becomes an expensive raw material by the extraction / purification process of only the active ingredient fraction. 2) Since it is naturally derived, it is difficult to stably supply raw materials for a long time when commercialized. 3) Since the content of active ingredients derived from natural plants depends on the seasons and the age of the trees, there is a possibility that indiscriminate collection and logging will be performed ignoring these. 4) When an unpurified extract or powder is used, the preparation also contains an unknown ingredient of effectiveness.
[0006]
  On the other hand, as described above, the ratio of negative ions to positive ions is completely reversed by destruction of natural environment or incineration of industrial waste, and as a result, it is originally weakly alkaline (pH 7.35 to 7.45) in vivo. A future problem will be to prevent body fluids, blood, and extracellular fluids from becoming weakly acidic due to an abnormal increase in positive ions, thereby preventing the occurrence and onset of various diseases associated therewith. In other words, a measure to return the ratio of negative ions to positive ions to the ideal value (6: 5) by constantly giving negative ions, which are insufficient in the urban environment where many people live, into the living body is a living body. It will be extremely important in the future to maintain homeostasis.
[0007]
  Natural minerals (ores) are electrons between atoms (e), Negative or negative ions, that is, electrons are constantly generated, so that mineral-derived negative ion generating materials have been commercialized. The main effect of this negative ion is to prevent the decrease of physiological functions (circulatory system, nervous system, immune system, endocrine system) of the living body by hormesis effect (cell division promotion, cell function activation, blood circulation promotion action, etc.) The improvement promotion effect is well known. In addition, it is well known that far-infrared generating materials have a diathermy effect (such as vasodilation, increased blood flow, and relaxation of muscle tone), and also have a function of generating negative ions. is there. These negative ion generating materials and far-infrared generating materials are commercialized in a very diverse and diverse product group, and these particle sizes are particles (10 to 50 μm) on the order of micrometers (μm).
[0008]
[Non-Patent Document 1]
Kojiro Futagami, etc. Modern Medicine: 17; 1369-1374, 1992
[Patent Document 1]
JP 2002-87989 A
[0009]
[Problems to be solved by the invention]
  However, the amount of negative ions (mm sievert / cm) generated from micrometer (μm) order particles or powders at the same level as bacteria and fungi, such as conventional negative ion generation materials and far infrared generation materials3) And nanometers (nm = 10) at the same level as the virus size-9m) When comparing the amount of negative ions generated from order-order particles, the negative ion generating material is similar to the Leonard effect found in water molecules (water molecules (mist) in water vapor in nature is 0.5 to 100 nm). It is considered that the finer the particle size, the more the generation amount and generation rate of electrons (the generation amount of negative ions) are increased and amplified, and it is possible to generate a wide range and always uniformly. In fact, it is said that the particle size of negative ions in the atmosphere is 1 to 20 nm, so by applying ultrafine powders of negative ion generation materials and far-infrared generation materials to the nanometer order, its applications and uses In particular, there is a great possibility that the application and application range for medical purposes will be further expanded.
[0010]
  Therefore, the present invention has been made in view of the above circumstances, and a negative ion generating material capable of sufficiently exhibiting the negative ion hormesis effect and the far-infrared diathermy effect.The Tolmari NOr far infrared ray generation materialNo bincho charcoalIt is an object of the present invention to provide a preparation and a functional food containing as a main ingredient.
[0011]
[Means for Solving the Problems]
  In order to solve the above problems, the present inventors have made a negative ion generating material.TourmalineOr far infrared ray generation materialNo bincho charcoalIs made into ultrafine powders of nanometer order, and these are mixed with cesum fat with anti-inflammatory activity, which has already been reported in research, collagen elastin degrading enzyme inhibitor and sugar ceramide as a growth factor receptor component. The present invention was completed by intensively studying the pharmacological activity of an animal in which an dermatitis wound site was experimentally induced or an animal in which immunodeficiency was experimentally induced in combination with the above-mentioned combination agent.
  That is, the present invention has an average particle size of nanometers (10-9m) Ultra fine powder to orderTourmaline and / or Bincho charcoalThe present invention relates to a preventive and / or ameliorating agent for reducing immune function comprising This invention is a negative ion generating materialTourmalineAnd far infrared ray generating materialNo bincho charcoalThe average particle size is nanometer (10-9m) Ultrafine powder to the order of the order enhances the negative ion hormesis effect and the far-infrared diathermy effect.
[0012]
  The present invention has an average particle size of nanometers (10-9m) Ultra fine powder to orderCharcoalAn inflammatory wound skin tissue regeneration function improvement promoter, a metabolic function improvement enhancer, and atopy, comprising as an active ingredient, at least one selected from sesame fat, sesame fat main component fraction, shea fat, and sugar ceramide Alternatively, the present invention relates to an allergic dermatitis improvement promoter, an ulcer skin disease improvement promoter, or a hair growth / hair growth promoter. In the present invention, the average particle size is nanometer (10-9m) Ultra fine powder to orderTourmaline and / or Bincho charcoalAnd an agent for preventing and / or improving immune function, comprising as an active ingredient at least one selected from sesame fat, sesame fat main component fraction, shea fat, and sugar ceramide. This invention synergistically amplifies the pharmacological activity by combining Bincho charcoal, which is made into ultra fine powder and enhanced diathermy effect, sesame fat, sugar ceramide and the like. Inflammatory wound skin tissue regeneration function improvement promoter means a preparation that mainly promotes regeneration and formation function of biological tissue components by assimilation and catabolism of various components in the living body. Is to relieve the deterioration of metabolic function and immune function that are likely to occur due to unforeseen biomodulation due to aging of skin / subcutaneous tissue constituents and related cell groups and environmental pollution (toxic substances, atoms, atomic group ions, etc.) And a formulation that promotes improvement.
[0013]
  The average particle size is nanometer (10-9m) Ultra fine powder to orderCharcoalRelates to functional foods. The average particle size is nanometer (10-9m) Ultra fine powder to orderCharcoalAnd at least one selected from sesame fat, sesame fat main component fraction, shea fat, and sugar ceramide.
[0014]
DETAILED DESCRIPTION OF THE INVENTION
The negative ion generating material of the present invention uses tourmaline, and the far infrared ray generating material uses Bincho charcoal.
[0015]
  Currently, the particle sizes of mineral and plant-derived material powders that are used and applied are at least 10 to 30 μm, but tourmaline or Bincho charcoal is micronized to the nanometer order. Ultrafine powdering can be performed, for example, by a pulverization technique manufacturing method described in Japanese Patent Publication No. 7-4553, and according to this manufacturing method, an ultrafine powder having a controlled average particle size and particle size distribution can be obtained. More specifically, it can be performed using a pulverizer manufactured by Aroma Chemical Machinery Co., Ltd. The nanometer order refers to a unit that is further 1/1000 smaller than 1 μm.
[0016]
  A commercially available product can be easily obtained as the sesame fat or sesame fat main component fraction. For example, sesame fat manufactured by Kuki Sangyo Co., Ltd. can be used. The sesame fat main component fraction refers to components mainly contained in sesame fat such as sesamin derivatives and phytosteroid derivatives, and these can be used together with sugar ceramide and the like. Shea butter (also referred to as shea butter) contains abundantly common main components (phytosteroids, essential unsaturated fatty acids, terpenoids) and sesame butter (Japanese Patent Application No. 2002-57972). Shea fat derived from shea fruit can be used, and such shea fat can be easily obtained from IBM Corporation.
[0017]
  Glyceramide is a kind of glycolipid that is contained in wheat germ, rice bran, rice bran, etc. and also in animal cells. The ceramide body can be produced by a chemical synthesis method, but it is extremely difficult and expensive to bind a sugar (particularly glucose) to the sphingosine skeleton. Therefore, as the sugar ceramide of the present invention, those derived from natural products can be suitably used, and commercially available products can be easily obtained. However, it is necessary to pay attention to those derived from wheat, which is a strong allergy-inducing food.
[0018]
  Ultra fine powderTourmalineOrBincho charcoal (hereinafter sometimes referred to as “ultra-fine powdered tourmaline” or “ultra-fine powdered Bincho charcoal”)Can be used alone as an active ingredient for prevention and / or improvement of immune function decline, but it can be used in combination with sesame fat, sesame fat main component fraction, shea fat or sugar ceramide to regenerate inflammatory wound skin tissue As an active ingredient of a function improvement promoter, a metabolic function improvement promoter, an atopic or allergic dermatitis improvement promoter, an ulcer skin disease improvement promoter, an immune function lowering prevention and / or improvement agent, or a hair growth / hair growth promoter. Can be used. The administration form of these drugs is generally applied and powdered, but is not limited thereto.
[0019]
  In the preparation of the present invention, the dosage form can be appropriately selected depending on the use, and a pharmaceutically acceptable excipient, disintegrant, ointment base, emulsifying base, milky base, cream base, medicinal washing base Can be used for dosage forms such as ointments, coatings, poultices, medicinal milk formulations, various medicinal or hair growth / hair growth gels and lotions, and powders, granules, tablets, capsules It can also be used as a medical preparation such as a suppository.
[0020]
  In addition, the preparation of the present invention can also be used as a medical preparation by blending with other ingredients or preparations (including those derived from animals and plants) having other medicinal effects and various biological function enhancement functions, as long as their medicinal effects are not lost. . For example, glucosamine, chondroitin, hyaluronic acid and vitamin C (ideal ratio: glucosamine: chondroitin: hyaluronic acid), which are basic and essential components necessary to re-synthesize self-collagen and cartilage components that gradually decrease with age. : Vitamin C = 10: 10: 2: 1), the self-collagen can be re-synthesized, so that it is not necessary to apply and take various animal and fish-derived collagen currently used . Moreover, it can also be used as an ointment or cosmetic (cream, gel, essence, lotion liquid, cosmetic soap, etc.) that promotes prevention, remission, and reduction of skin spots and wrinkles. Furthermore, by adding chitosan (powder, water-soluble) derived from crustaceans (crabs, shrimps, etc.) known to have a strong antiallergic action and immunostimulatory action, the action of the above-mentioned preparations of the present invention It is also possible to enhance the effect synergistically and effectively.
[0021]
  In addition, in particular, with the expectation of the metabolic function improvement enhancement action and the immune function decrease prevention improvement action,Ultra fine powder tourmalineAndUltra fine powdered Bincho charcoalAlternatively, a functional food containing a combination of sesame fat, sesame fat main component fraction, shea fat, and sugar ceramide can be provided. According to this functional food, it is possible to prevent / improve the decrease in biological homeostasis that is remarkable in aging changes, and it may be blended in nursing foods and dietary supplements. It can also be added to solid foods such as jelly and yogurt.
[0022]
  In the preparation of the present invention,Ultra fine powder tourmalineAndUltra fine powdered Bincho charcoalOr the blending ratio of sesame butter, sesame butter main component fraction, shea butter, sugar ceramide,Ultra fine powder tourmalineIs 0.2 to 0.6 parts by weight,Ultra fine powdered Bincho charcoal0.1 to 0.5 parts by weight, sesame fat, sesame fat main component fraction or shea fat is preferably 0.5 to 5.0 parts by weight, and sugar ceramide is preferably 0.1 to 0.3 parts by weight. Below these lower limits, sufficient synergistic effects between additives may not be obtained, and when the upper limit is exceeded, immunocompetent cells, particularly macrophages that are the first cells at the time of immune function activation This is because the antigenicity becomes supersaturated and may prevent the functionality of macrophages. Taking these into consideration, in order for the various preparations of the present invention to exert a sufficient effect, the intake of the various preparations is preferably 5 to 10 g / day per 50 kg body weight, and this is taken 2-3 times a day. They may be used separately. Of course, taking the age, symptom, physical condition, etc. of the subject to be used can be increased or decreased as appropriate.
[0023]
【Example】
  EXAMPLES Next, although an Example is given and this invention is demonstrated, this invention is not limited to a following example.
[0024]
  [Example 1] Experimental inflammatory dermatitis wound site preparation method and inflammation site area measurement method
  0.1 ml (24 mg / ml, 75 mg / kg) of sodium thiopental anesthetic (labonal, Manyu Pharmaceutical) was injected into the abdominal cavity of a 7-week-old ddY normal female mouse (average body weight: 32 g, manufactured by SLC). Administered. For anesthetized animals, completely remove the hair on the back with an electric hair clipper and a hair removal cream, and then place a special electric dryer (caliber: 3 cm, 800 V / 100 W) at right angles to the back of the mouse. Install and irradiate the hair removal part back surface from a height of 10cm for 60 seconds (80 ° C), atopic / allergic skin inflammation site (average 8cm2) Was produced (see FIG. 1). In this experimental method, it corresponds to a single burn (a wound extending from the stratum corneum to the epidermis layer). In addition, when the white blood cell classification (staining method) and immunoglobulin E (IgE) antibody titer (EIA method) in animal blood prepared by this method were measured, basophils and antibody titers were significantly higher than those in the normal control group. Since it was elevated, it was confirmed that atopic dermatitis / allergic dermatitis was induced experimentally. The cellophane paper was applied to the back inflammation skin surface of the mouse under anesthesia for 28 days immediately after preparation of the skin inflammation site, the inflammation site surface and the recurrent hair site surface were traced with a marker, and an image analysis device (Modulator System MOP-AM03, Each area was measured at Kontron, Germany). The wound area of the mouse irritated skin surface was determined by the following formula.
        Wound area (mm2) = Total area of inflammation skin surface-total area of recurrent hair surface
[0025]
  [Example 2] Method for preparing experimental formula cream
  In the cream base containing no various ingredients, 0.5 parts by weight of ultrafine powdered tourmaline, 0.5 parts by weight of ultrafine powdered Bincho charcoal, and 3.8% of sesame fat with respect to 100 parts by weight of various drugs described below. Part by weight and sugar ceramide were mixed at a ratio of 0.2 part by weight. Moreover, tourmaline and Bincho charcoal were pulverized to an average particle size of 10 nm and 30 nm, respectively, using a pulverizer manufactured by Aroma Chemical Machinery Co., Ltd.
[0026]
  [Example 3] Reduction and healing transition of experimental inflammatory skin wound surface
  This experimental system consists of (1) cream base single application control group (2) sesam fat / sugar ceramide (hereinafter also referred to as SC) compound application group (3) ultra fine powdered Bincho charcoal (hereinafter referred to as nano / C) SC) containing SC (hereinafter also referred to as nano-C-SC) compounding group (4) nano-TC-SC obtained by adding ultra-micronized tourmaline (hereinafter also referred to as nano-T) to nano-C-SC A total of 4 groups (each group: 5 animals) of the compounding agent application group were prepared, and the following experiment was conducted. In other words, immediately after the experimental dermatitis was caused on the dorsal skin surface of the mouse by the method described in Example 1 (Day 0), each of the above preparations prepared in Example 2 on Days 1, 3, and 5 (0.5 g / spater / mouse) was applied and spread with a glass condense rod (4 times in total), and then the area of the inflamed site was measured by the method of Example 1 over 28 days. The results are shown in Table 1 (see FIGS. 2 and 3). As shown in this table, the wound area immediately after the inflammatory skin wound surface is 6.30 ± 0.45 cm.2Met. When an experiment was conducted using such experimental inflammation-inducing mice, the inflammatory skin wound area on days 7, 14, and 21 in the cream base-coated control group was 5.88 ± 0.31, 3. 28 ± 0.38, 2.02 ± 0.45cm2As the number of days passed, the healing tendency of the inflammatory site was gradually observed. In contrast, a significant difference (risk rate: 5% or less, test method: Student t-test method) was observed on the 14th day in the SC compounding agent application group. On the other hand, the healing promotion effect of the nano / C-SC combination application group was more remarkable than that of the SC combination application group, and significance (risk rate: 5% or less) was already observed on the seventh day. Moreover, the healing effect of the nano / TC-SC combination drug application group is stronger than that of the nano / C-SC combination drug application group, and on day 7, a significant difference with a risk rate of 1% or less is shown. The wound areas on days 14 and 21 are 3.71 ± 0.58, 0.63 ± 0.14 and 0.01 ± 0.02 cm.2Met. On the other hand, the area of hair growth significantly increased with the passage of days due to the application of the nano series compounding agent, so these compounding agents have hair growth / hair growth promoting action, that is, hair follicle cells (hair root, It has also been clarified that the hair papilla will also have a growth-promoting action.
[0027]
[Table 1]
Figure 0003884693
[0028]
  [Example 4] Transition of percentage of mice completely cured of experimental inflammatory skin wound surface
  A total of 5 groups (each group: 10 animals) including the nano-T-SC compound application group in which ultrafine powdered tourmaline (T) was added to the SC compound agent was added to the four groups of experimental systems described in Example 3 The change in the percentage of complete healing of the inflammatory skin wound surface on the 21st and 28th days was examined. The results are shown in Table 2 (see FIG. 4). As shown in this table, the complete healing rate in the cream base application control group was only 10% on the 21st day and only 20% on the 28th day, but increased slightly in the SC compound application group, The complete cure rate on day 28 was 40%. On the other hand, by adding ultra-fine powdered Bincho charcoal (C) or ultra-fine powdered tourmaline (T) to this SC compounding agent, the complete healing rate is further increased, reaching 50-60% on the 21st day. did. On the other hand, in the nano / TC-SC combination drug application group, a complete cure rate of 80% was already observed on the 21st day. From these results, it was confirmed that the healing of the inflammatory skin wound surface was synergistically promoted by mixing and blending the ultrafine powdered negative ion generating material and the far infrared ray generating material. That is, it was suggested that it may be due to the synergistic effect of the negative ion hormesis effect and the far infrared diathermy effect.
[0029]
[Table 2]
Figure 0003884693
[0030]
  [Example 5] Number of infiltrating cells in experimental inflammatory skin tissue and cell classification
  10% fetal calf serum-added eagle MEM (heparin: 4 units / ml) culture solution (hereinafter referred to as “the dermal layer”) from the wound skin epidermis layer to the dermis layer on the 7th day after application of the various formulations to the experimental system 5 group described in Example 4 After injecting 5 ml of the culture broth and thoroughly squeezing the back skin, the infused culture broth was collected with a syringe for 5 ml, and 1.0 ml thereof was transferred to a plastic microplate (diameter: 30 mm, 6 wells). After incubating the microplate at 37 ° C. for 2 hours, the culture solution is gently removed, and the wells are washed with phosphate buffer, fixed with methanol, and Giemsa stained. Calculated. As a result, as shown on the left side of Table 3, the total number of infiltrating cells in the SC compounding agent application group (average: 2.2 × 104(Co / well) increased to a value approximately twice that of the cream base-coated control group, but no significant difference was observed between the two groups. On the other hand, by adding ultrafine powdered Bincho charcoal or ultrafine powdered tourmaline to this SC formulation, the total number of infiltrated cells was remarkably increased, which was about 7 times that of the cream base application control group. In addition, the total number of infiltrating cells in the nano-TC-SC combination drug application group in which these two types of ultrafine powders were mixed and mixed was actually 10 times (average 2.6 × 10 65The risk factor was 0.01% or less.
  On the other hand, when these infiltrating cells were classified, as shown on the right side of Table 3, in the cream base-coated control group, the number of lymphoid cells was the largest, with an average of 89.5%, macrophage-like cells and epithelial / Fibroblasts were only 8.2% and 2.3%. This tendency was the same result in the SC compounding agent application. However, macrophage-like cells (MP, average 46-52%) by adding ultrafine powdered Bincho charcoal or ultrafine powdered tourmaline to these SC formulations or by adding these two ultrafine powders And epithelial / fibroblasts (average 6 to 20%) were remarkably increased, particularly in the nano / TC-SC combination drug application group (MP: average 52.2%, Epithelial / fibroblasts: average 20.4%).
  From these results, the addition of ultrafine powdered Bincho charcoal and ultrafine powdered tourmaline stimulates immune function and further promotes the division and proliferation of cells related to skin and subcutaneous tissue. It was estimated that
[0031]
[Table 3]
Figure 0003884693
[0032]
  [Example 6] Histopathological examination of skin and subcutaneous tissue of experimental inflammatory skin wound surface
  Next, the reasoning described in Example 5 above (the increase in skin tissue-related epithelial cells and fibroblasts due to the addition of ultrafine powdered Bincho charcoal or ultrafine powdered tourmaline to the SC compounding agent is a negative ion hormesis effect. The following studies were conducted in order to verify that the resynthesis of collagen proteins such as collagen and elastin would also be promoted. Among the five groups described in Example 4, the average inflammation site area on day 14 of the cream base application control group, the nano-T-SC combination application group, and the nano / C-SC combination application group was the most. The skin tissue on the back wound surface of a nearby mouse was excised and treated according to a conventional method. That is, after dehydration treatment (alcohol concentration gradient), fixation (1% glutaraldehyde, 1% paraformaldehyde mixed solution) and paraffin embedding, a skin tissue section was prepared. Connectic tissue (collagen) proteins are stained by elastica and fungison staining methods that specifically dye proteins, and the progress of regeneration and formation of connective tissues (collagen fibers, elastic fibers, collagen, elastin, etc.) in the subcutaneous tissue is observed. Observed below. The result is shown in FIG. In the cutaneous tissue section image (right end of FIG. 5) immediately after the preparation of the inflamed site, there is no portion that should be dyed red to pink with the staining solution, and the skin layer and the tissue itself may be completely necrotic. confirmed. In contrast, in the skin tissue section image of the cream base-coated control group, the pink-stained portions are scattered, and the infiltration of the epithelial (circular) cells and fibroblasts (spindle-shaped) groups is stratum corneum. From the lower basement membrane to the dermal layer and subcutaneous tissue, it was confirmed that the regenerative mechanism of the entire skin tissue, including the basement membrane formation process, is still in the initial stage. On the other hand, in the tissue slice images of the nano-C-SC compounding agent application group and the nano-T-SC compounding agent application group by adding ultrafine powdered Bincho charcoal or ultrafine powdered tourmaline, the above-mentioned Almost no cell group was observed from the dermis layer to the subcutaneous tissue layer, but the entire surface of the tissue was stained in bright pink.
  That is, the formation of collagen proteins (collagen, elastin) was almost completed, and the re-formation of the stratum corneum, basement membrane, epidermis layer and dermis layer was finished. This is because the increase phenomenon of the epithelial / fibroblastic cell group was remarkable in the nano / C-SC combination application group and the nano / T-SC combination application group on the seventh day shown in Table 3. On the 14th day, the resynthesis of collagen proteins was completed by these cell groups, and as a result, it was confirmed that the whole tissue section was stained in deep pink with the feedback of these cell groups. It was.
[0033]
  [Example 7] Method for producing dexamethasone-treated immune-deficient animal
  Using the adrenal cortex hormone system dexamethasone (Decadron, manufactured by Tanabe Seiyaku Co., Ltd.), the present inventors performed according to a modified method (J. Jpn. Associ. Dis. 70: 574-582, 1996). Specifically, 0.3 ml (11.5 mg / kg / day) of dexamethasone (DM) solution (1.0 mg / ml) was placed into the peritoneal cavity of 5-week-old female mice (average body weight 26 g) at 0, 1, 3 and 5 By inoculating a total of 4 times on the day, mice with reduced or attenuated immune function were prepared (hereinafter referred to as DM-treated mice).
[0034]
  [Example 8] Effect of ultrafine powdered trimarin and ultrafine powdered Bincho charcoal on the number and percentage of cells exuded into the peritoneal cavity of DM-treated mice
  For the DM-treated mice prepared in Example 7 (each group: 3 animals), after final DM treatment (4th inoculation), on the first day, a solution of ultra-micronized tourmaline and ultra-micronized Bincho charcoal 0 2 ml (0.1 mg / ml physiological saline: 7.7 mg / kg) was administered intraperitoneally to each mouse. As a control group, a non-administration normal group and a DM treatment alone group (each group: 3 animals) were prepared. After administration of the above two kinds of ultrafine powder lysates, the peritoneal exudate cells were cultured in the same manner as in Example 5 on the third day, and washed in the same manner as in Example 5. After fixation and staining, the total number of cells on the wells of the microplate and the classification of various cells were calculated under a microscope. The results are shown in Table 4 (see FIG. 6).
  As shown on the left side of this table, the non-administered normal control group (average 2.2 × 10 6)6Co / well) and DM treatment alone group (2.6 × 10 6)5Significant difference between (co / well) (risk rate: 0.05% or less), and the number of immunocompetent cells significantly decreased after 4 treatments with DM, so that DM has a remarkable effect on the immune function. It was estimated that. When such ultra-micronized tourmaline or ultra-micronized Binchotan charcoal was administered intraperitoneally to DM-treated mice to such immune function-deficient / deficient mice, there was a marked increase in the total cell number in any administration group, The number is close to or higher than that of the non-administered normal control group (average: 3.0 to 4.5 × 106(Risk rate: 0.01% or less). On the other hand, as shown on the right side of this table, the group of cells that decrease by DM treatment is macrophages, and the ultra-micronized tourmaline and ultra-micronized Bincho charcoal that have been tested have the effect of increasing the decreased number of macrophages again. That is, these ultrafine powders have been shown to exhibit immune function recovery action, particularly macrophage function enhancement effect.
[0035]
[Table 4]
Figure 0003884693
[0036]
  [Example 9] Enhancement effect of recovery of phagocytic function on intraperitoneal macrophages of DM treated mice by micronized tourmaline and micronized Bincho charcoal
  The following experiment was conducted on the reasoning described in Example 8 (see Table 4), that is, the presence or absence of the action of improving or promoting the macrophage function of tourmaline or Bincho charcoal that was micronized. That is, for the three groups described in Example 8, 1 ml of the peritoneal exudate collected by the same method was transferred to a microplate, cultured at 37 ° C. for 3 hours, washed, and then heat treated methicillin resistant yellow staphylococci (MRSA). ) Add 1 ml of the bacterial solution prepared so that the number of bacteria is 20 viable units (CFU) of MRSA bacteria (MOI = 20) per cultured cell, and further incubate at 37 ° C. for 2 hours to perform the phagocytosis experiment. went. Thereafter, for samples prepared according to the method described in Example 5, the phagocytosis rate of macrophages (MP) against MRSA bacteria and the number of MRSA bacteria phagocytosed per MP1 were calculated. The results are shown in Table 5 (see FIG. 7). As shown on the left side of this table, the phagocytosis rate of MRSA bacteria of macrophages (MP) derived from the non-administered normal control group averaged 46.5%, but the phagocytosis rate significantly decreased by DM treatment (average) 4.9%). By intraperitoneally administering ultrafine powdered tourmaline or ultrafine powdered Bincho charcoal to such DM-treated mice, the MP phagocytosis rate increased to 56.6% and 67.2% on average, and normal controls It was a value exceeding the group MP. On the other hand, as shown on the right side of Table 5, the average number of MRSA bacteria phagocytosed per one macrophage (MP) derived from the normal control group was 4.8, whereas the average number of MPs in the DM-treated group was 0. The phagocytic function of MP was significantly impaired. However, when the two ultrafine powders tested were administered intraperitoneally, the phagocytic function of the attenuated macrophages was remarkably recovered and enhanced (average 9.4 to 12.1%) and treated with DM. The phagocytic function of MP from the group was actually 11-13 times.
[0037]
[Table 5]
Figure 0003884693
[0038]
  [Example 10] Examination of safety test
  1) 50% lethal dose
  5 groups of ddY female and male mice (5 weeks old) were prepared, and the number of deaths of mice due to oral administration and intraperitoneal administration of ultrafine powdered tourmaline and ultrafine powdered Bincho charcoal was recorded over 7 days. The 50% lethal dose of these preparations was determined according to the Behrens Carver method. As a result, the 50% lethal dose by oral administration of both preparations was 1700 mg / kg or more regardless of sex, and the 50% lethal dose by intraperitoneal administration was 5900 mg / kg.
  2) Photosensitization (allergic), primary skin irritation test
  Photosensitization (allergy) and primary skin irritation tests were conducted on healthy individuals (30 persons) with nano-TC-SC combination cream or lotion, and were negative in all tests.
[0039]
  [Example 11] Inflammatory wound skin tissue regeneration function improving agent
  Each component shown in Table 6 was mixed with 10 g of the cream base, adjusted to 100 g with the cream base, and the intended preparation was produced. In addition, this prescription is a preparation which also has the purpose of renewing collagen in the skin.
[0040]
[Table 6]
Figure 0003884693
[0041]
  [Example 12] Ointment for anti-atopic / allergic skin inflammation
  Each component shown in Table 7 was added to and mixed with 10 g of the cream base, and the total amount was adjusted to 100 g with white petrolatum to prepare the intended preparation.
[0042]
[Table 7]
Figure 0003884693
[0043]
  [Example 13] Functional food
  Table 8Were added to yoghurt raw material, jelly raw material, or pudding raw material to make a total amount of 100 g, and a functional food for promoting metabolic function enhancement and prevention / improvement of immune function decline was produced.
[0044]
[Table 8]
Figure 0003884693
[0045]
【The invention's effect】
  Since this invention is comprised as mentioned above, there exist the following effects.
  According to the present invention, the average particle size is nanometer (10-9m) Ultra fine powder to orderTourmaline and / or Bincho charcoalAs an active ingredient, the hormesis effect of negative ions and the diathermy effect of far-infrared rays are enhanced, and the effect of preventing and / or improving the decrease in immune function is excellent.
[0046]
  According to the present invention, the average particle size is nanometer (10-9m) Ultra fine powder to orderCharcoalAnd at least one selected from sesame fat, sesame fat main component fraction, shea fat and sugar ceramide, or having an average particle size of nanometer (10-9m) Ultra fine powder to orderTourmaline and / or Bincho charcoalAnd one or more kinds selected from sesame fat, sesame fat main component fraction, shea fat and sugar ceramide are effective ingredients, so that the hormesis effect and diathermy effect were enhanced.TourmalineAndCharcoal, Synergistic amplification of pharmacological activity by combining sesame butter, sugar ceramide, etc., so that various excellent pharmacological activities are achieved, especially inflammatory wound skin tissue regeneration function improvement promoting action, metabolic function improvement promoting action, A preparation excellent in an atopic or allergic dermatitis improvement promoting effect, an ulcerative skin disease improvement promoting effect, an immune function reduction preventing and / or improving effect or a hair growth / hair growth promoting effect can be provided.
[0047]
  According to the present invention, the average particle size is nanometer (10-9m) Ultra fine powder to orderCharcoalOr an average particle size of nanometer (10-9m) Ultra fine powder to orderCharcoalCan be added to foods as functional foods in combination with one or more selected from sesame fat, sesame fat main component fraction, shea fat, and sugar ceramide. A meal having a function to prevent and improve functional deterioration can be taken in daily eating habits.
[Brief description of the drawings]
FIG. 1 Experimental method for producing inflammatory skin wound surface on the back of mouse and image of back wound surface of mouse immediately after preparation of atopic / allergic skin wound surface
[Fig. 2] Back wound image of mice 7 days after application of various compounding agents
FIG. 3 is an image of a back wound surface of a mouse 14 days after application of various compounding agents.
FIG. 4 is an image of the back wound surface of a mouse on the 21st day after application of various combination drugs.
FIG. 5: Photomicrographs of subcutaneous tissues of dorsal wounds of mice 14 days after application of various combination drugs.
FIG. 6: Photomicrograph of a group of immunocompetent cells in the peritoneal cavity of DM-treated immunodeficient mice.
[Fig. 7] MRSA phagocytosis of DM-treated immunodeficient mouse peritoneal macrophages

Claims (9)

平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化されたトルマリン及び/又は備長炭を有効成分として含む免疫機能低下予防及び/又は改善剤。A preventive and / or ameliorating agent for lowering immune function comprising, as an active ingredient, tourmaline and / or Bincho charcoal, whose average particle size is micronized to the order of nanometers (10 −9 m). 平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、
セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、
を有効成分として含む炎症性創傷皮膚組織再生機能改善促進剤。
Bincho charcoal , which has been micronized to an average particle size of the order of nanometers ( 10-9 m),
One or more selected from sesame fat, sesame fat main component fraction, shea fat, sugar ceramide,
An inflammatory wound skin tissue regeneration function improving promoter comprising
平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、
セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、
を有効成分として含む新陳代謝機能改善亢進剤。
Bincho charcoal , which has been micronized to an average particle size of the order of nanometers ( 10-9 m),
One or more selected from sesame fat, sesame fat main component fraction, shea fat, sugar ceramide,
A metabolic function-improving enhancer containing as an active ingredient.
平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、
セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、
を有効成分として含むアトピー性又はアレルギー性皮膚炎改善促進剤。
Bincho charcoal , which has been micronized to an average particle size of the order of nanometers ( 10-9 m),
One or more selected from sesame fat, sesame fat main component fraction, shea fat, sugar ceramide,
An atopic or allergic dermatitis improvement promoter containing as an active ingredient.
平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、
セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、
を有効成分として含む潰瘍性皮膚疾患改善促進剤。
Bincho charcoal , which has been micronized to an average particle size of the order of nanometers ( 10-9 m),
One or more selected from sesame fat, sesame fat main component fraction, shea fat, sugar ceramide,
An ulcerative skin disease amelioration promoter comprising as an active ingredient.
平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化されたトルマリン及び/又は備長炭と、
セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、
を有効成分として含む免疫機能低下予防及び/又は改善剤。
Tourmaline and / or Bincho charcoal with an average particle size of ultrafine powder to the nanometer (10 −9 m) order;
One or more selected from sesame fat, sesame fat main component fraction, shea fat, sugar ceramide,
A preventive and / or ameliorating agent for lowering immune function comprising as an active ingredient.
平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、
セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、
を有効成分として含む発毛・育毛促進剤。
Bincho charcoal , which has been micronized to an average particle size of the order of nanometers ( 10-9 m),
One or more selected from sesame fat, sesame fat main component fraction, shea fat, sugar ceramide,
Hair growth / hair growth promoting agent containing as an active ingredient.
平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭を含む機能性食品Functional food containing Bincho charcoal that has been micronized to an average particle size of the order of nanometers (10 -9 m) 平均粒径がナノメートル(10−9m)オーダーにまで超微粉末化された備長炭と、
セサム脂、セサム脂主要成分画分、シア脂、糖セラミドから選ばれた1種以上と、
を含む機能性食品。
Bincho charcoal , which has been micronized to an average particle size of the order of nanometers ( 10-9 m),
One or more selected from sesame fat, sesame fat main component fraction, shea fat, sugar ceramide,
Functional food containing.
JP2002299984A 2002-10-15 2002-10-15 Formulations and functional foods that contain ultrafine powdered negative ion generating materials and far-infrared generating materials as active ingredients Expired - Lifetime JP3884693B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002299984A JP3884693B2 (en) 2002-10-15 2002-10-15 Formulations and functional foods that contain ultrafine powdered negative ion generating materials and far-infrared generating materials as active ingredients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002299984A JP3884693B2 (en) 2002-10-15 2002-10-15 Formulations and functional foods that contain ultrafine powdered negative ion generating materials and far-infrared generating materials as active ingredients

Publications (2)

Publication Number Publication Date
JP2004131453A JP2004131453A (en) 2004-04-30
JP3884693B2 true JP3884693B2 (en) 2007-02-21

Family

ID=32288959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002299984A Expired - Lifetime JP3884693B2 (en) 2002-10-15 2002-10-15 Formulations and functional foods that contain ultrafine powdered negative ion generating materials and far-infrared generating materials as active ingredients

Country Status (1)

Country Link
JP (1) JP3884693B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004261146A (en) * 2003-03-04 2004-09-24 Tokyo Tourmaline:Kk Nutritive assistance food
JP2005341828A (en) * 2004-06-01 2005-12-15 Nohken Techno Kk Feed improving material and method for producing the same
JP2006143605A (en) * 2004-11-16 2006-06-08 Miyao Shunsuke Method for producing percutaneously administrative agent and orally administrative agent each promoting fibroblast proliferation
JP2007169577A (en) * 2005-12-19 2007-07-05 Cb:Kk Oil and fat composition containing carbon fine particle, and method for producing the same
JP2011132128A (en) * 2009-12-22 2011-07-07 Katsuaki Uno Inhibiter
WO2012156805A1 (en) * 2011-05-18 2012-11-22 Rhodia Poliamida E Especialidades Ltda Threads, fibres or filaments including mineral fillers and textile item and medical device obtained from said threads for healing the skin
JP6336729B2 (en) * 2013-09-13 2018-06-06 株式会社トータルサポートサービス Cosmetic base material containing lava stone and cosmetics using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045608A (en) * 1996-04-17 1998-02-17 Toya Seishi Kk Zeolite-containing therapeutic agent for wound
JPH10234337A (en) * 1997-02-28 1998-09-08 Best Fuyuujohn Kk Tourmaline ore containing food and external usage agent
JP2001020151A (en) * 1999-07-07 2001-01-23 Matsushita Electric Ind Co Ltd Minus ion generator
JP3620367B2 (en) * 1999-08-12 2005-02-16 和 大田 Hair restorer
JP2003119617A (en) * 2001-10-12 2003-04-23 Kanebo Ltd Minus ion generating porous acrylic fiber and method for producing the same
JP2003252768A (en) * 2001-12-27 2003-09-10 Bio X:Kk Skin treatment material utilizing negative ion generator

Also Published As

Publication number Publication date
JP2004131453A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
WO2015156339A1 (en) Immune balance adjustment agent
US9271956B2 (en) Companion cosmetic compositions
JP5540474B2 (en) Nerve elongation inhibitor
TW200911279A (en) Compositions, uses, and method of making wound care products from naturally occurring food ingredients
TW200826953A (en) Agonist for healing living organisms
JP3884693B2 (en) Formulations and functional foods that contain ultrafine powdered negative ion generating materials and far-infrared generating materials as active ingredients
CN112022895A (en) Composition for skin barrier repair and preparation method thereof
KR100999870B1 (en) Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata Thub and Ulmus davidana var.Japonica as an active ingredient
JP2003212786A (en) Skin care medicament with bamboo extract component as active ingredient
AU2012323427B2 (en) Egg preparation with regenerating, analgesic and/or anti-inflammatory properties
JP2010006801A (en) Lactic acid bacterium formulation and process for its production
KR20090124815A (en) Cosmetic composition and manufacturing method thereof
WO2017069793A1 (en) Vaginal gel compositions and methods of use thereof
KR101366549B1 (en) A Method for Preparing a Marine Animal Fermentation Product and the Product Obtained Thereby and Uses Thereof
JP2010024211A (en) Cell proliferation promoting agent
CN103710264B (en) A kind of broken wall supplementary additive of Ganoderma spore
JP2018203674A (en) Sebum secretion promoter and external composition
KR101897720B1 (en) Cosmetic or pharmaceutical composition for promoting hair growth comprising Tenebrio molitor fractions
US9364510B2 (en) Botanical composition and methods of manufacture and use
JPH10120556A (en) Skin preparation for improving sputum for external use
KR20160057183A (en) Cosmetic composition containing the fermented extract of allium monanthum, allium scorodorpasum, allium tuberosum, allium fistulosum and scilla scilloides
JP6656890B2 (en) Filaggrin production promoter
CN106798826A (en) Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine
JP6375100B2 (en) Anti-aging agent, whitening agent, skin cosmetics and food and drink
JP4599480B2 (en) Infectious immune function enhancer, metabolic function promoter, biological function deterioration prevention / amelioration agent, and functional foods containing these

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060627

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20060714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20061110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20061117

R150 Certificate of patent or registration of utility model

Ref document number: 3884693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091124

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101124

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101124

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121124

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131124

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term